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CELLULAR AND INFECTION MICROBIOLOGY
Multidrug resistant Staphylococcus aureus 
strains are emerging and current antibiot-
ics are not efficacious against such strains. 
Therefore, there is an urgent need to develop 
vaccines to target this pathogen. However, 
both active and passive immunization strat-
egies have thus far failed to show efficacy in 
humans. There are several potential reasons 
behind the disappointing results of clinical 
trials, however, we believe that just a few of 
them, which are common to all the trials, 
determined their downfall. First of all, pre-
clinical results obtained with antigens tested 
in clinical trials were likely overestimated by 
vaccine manufacturers. Furthermore, vac-
cines tested in humans to date, since they 
all targeted single antigens, were probably 
disproportionate to the complex pathogenic 
mechanisms of the bacterium. In addition, 
the lack of known correlates of protection 
in humans has severely limited the ability 
to interpret both preclinical and clinical 
data. Finally, the vaccines did not contain 
new generation adjuvants, which may be 
critical in augmenting antibody production 
and steering the T-cell response toward the 
proper profile of cytokine production.
Antigens tested in clinicAl triAls 
generAte only pArtiAl protection 
in AnimAl models
We often read in recent publications the 
statement: “the vaccine failed in clinical 
trials despite being protective against 
staphylococcal infection in animal 
models.”
We think that this parallel should not be 
made.
Staphylococcus aureus capsular polysaccha-
rides type 5 and 8 (CP5 and 8) conjugated 
with recombinant Pseudomonas aeruginosa 
exoprotein A were included in the first vac-
cine tested in humans, StaphVax (by Nabi 
Biopharmaceutical), which failed in phase 
III clinical trial in 2005. No consistent pro-
served and expressed  throughout  different 
S. aureus strains and is an important viru-
lence factor (Kuklin et al., 2006; Kim et al., 
2010). However, as an antigen, the protein 
generated only partial protection in lethal 
infection mouse models (Kuklin et al., 
2006; Stranger-Jones et al., 2006).
On top of active immunization, a num-
ber of passive approaches have also been 
undertaken: Veronate, based on polyclonal 
antibodies against the S. aureus surface 
protein ClfA; Altastaph, containing CP5 
and CP8 antibodies purified from subjects 
vaccinated with StaphVax; Tefibazumab, 
monoclonal antibodies against ClfA; and 
Aurograb, single chain antibodies against 
an ABC transporter of the pathogen. They 
all failed to show efficacy against S. aureus 
infection in humans (Schaffer and Lee, 
2008; Ohlsen and Lorenz, 2010; Otto, 2010).
The vaccines tested so far in humans 
differ quite substantially in the nature 
of the immunogen used, the immuniza-
tion approach and the target population. 
However, there is an obvious commonal-
ity between them: they all target a single 
component of the pathogen. Since S. aureus 
expresses a plethora of toxins and immune 
evasion factors, efficacy of monovalent vac-
cines is likely to be insufficient in humans 
and this is reflected by partial protection 
achieved in animal models.
VAccines so fAr tested in clinicAl 
triAls Are not the best AVAilAble 
option
We strongly believe that a multivalent vac-
cine is needed against S. aureus. Indeed, it 
has already been demonstrated that protein 
combinations can generate additive pro-
tection (Stranger-Jones et al., 2006; Kim 
et al., 2011). In particular a combination 
of four surface proteins (IsdB, IsdA, SdrD, 
and SdrE) was shown to protect mice from 
lethal infection with S. aureus Newman 
strain with greater efficacy than any of the 
single components (Stranger-Jones et al., 
tective efficacy appears to be associated with 
CP8 immunization (Tuchscherr et al., 2008; 
Cook et al., 2009), and this may have sig-
nificantly contributed to the clinical fail-
ure of StaphVax. Indeed, CP8 is expressed 
by approximately 40% of the circulating 
strains and therefore the poor protective 
efficacy associated with this antigen could 
have significantly affected the trials. On 
the other hand, although vaccination with 
CP5 has been shown to be efficacious in ani-
mal models of staphylococcal infection, S. 
aureus USA300, one of the most important 
clones worldwide, has recently been found 
to elaborate no detectable capsule because 
of a point mutation in the promoter region 
of cap-5, necessary for CP5 biosynthesis 
(Montgomery et al., 2008). Furthermore, 
the role of CPs in S. aureus virulence is not 
clear and their expression is limited to the 
stationary phase (O’Riordan and Lee, 2004; 
Schaffer and Lee, 2008).
Given all these variables, we think that 
the only approach to reliably measure vac-
cine efficacy in animal models is to perform 
challenge experiments with a large collec-
tion of strains representative of the circulat-
ing staphylococcal clones, and use different 
models with different routes of infection as 
well as low and large bacterial inocula. By 
doing that, vaccine efficacy will be tested in 
a number of different conditions, some of 
which may be more favorable than others. 
Ideally, a vaccine should consistently protect 
in all conditions.
A second failure occurred with an 
active immunization strategy based on a 
single surface staphylococcal protein, IsdB 
(Kuklin et al., 2006; Spellberg and Daum, 
2011). The phase II/III vaccine clinical trial 
was interrupted, however, the precise rea-
son for its premature interruption is not 
yet completely understood (Spellberg and 
Daum, 2011). IsdB is a protein which medi-
ates iron uptake from hemoglobin. The pro-
tein shows several favorable characteristics 
as a vaccine candidate. Indeed, IsdB is con-
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the human specificity. For example SCIN, 
CHIPS, and SAK, which directly or indi-
rectly inhibit C3 convertase, C5a receptor, 
and C3b, respectively, are all human spe-
cific (Rooijakkers et al., 2005; Serruto et al., 
2010b). It is therefore likely that the contri-
bution of these factors in evading the host 
immune response is underestimated in ani-
mal models. Therefore, protective efficacy 
of vaccines tested in animals may generally 
be greater than in humans. Development of 
improved animal models, such as human-
ized mice, and reliable surrogates of protec-
tion, such as the opsonophagocytosis assay, 
is another critical aspect that the scientific 
community needs to address to increase 
the likelihood of success of S. aureus vac-
cines. On the other hand, the presence of 
such mechanisms indicates that antibody-
mediated protection is potentially impor-
tant against S. aureus. Therefore, to develop 
efficacious vaccines we need to understand 
how to avoid or compensate for the detri-
mental effect of complement evasion factors 
on the host immune response.
cell-mediAted immunity mAy be A 
key element of S. aureuS 
VAccines
Patients with disruption of anatomical 
barriers, and those with quantitative and 
qualitative T-cell or neutrophil disorders 
are definitively at increased risk of devel-
oping staphylococcal infections (Spellberg 
and Daum, 2011).
These observations were recapitulated in 
animal models demonstrating that B cell-
deficient mice were no more susceptible 
to systemic infection caused by S. aureus 
compared with wild-type mice (Spellberg 
et al., 2008), while Tcell-deficient (Spellberg 
et al., 2008), IFN-γ-deficient (Spellberg 
et al., 2008; Lin et al., 2009), TNF-deficient 
(Hultgren et al., 1998), and dual IL-17A/F-
deficient (Ishigame et al., 2009) mice were 
hypersusceptible to S. aureus infection. 
Furthermore, Th17 cells were necessary 
for vaccine-induced protection against 
S. aureus infection by enhancing neutro-
phil recruitment to sites of infection, and 
killing of the bacteria (Lin et al., 2009). 
Superoxide-deficient mice (a model of 
chronic granulomatous disease) were also 
more susceptible to infection. Altogether, 
these data indicate that protection against 
S. aureus infections requires intact phago-
cytic function and is markedly enhanced by 
et al., 2010). On the other hand, in vitro 
assays have shown that antibodies can have 
a direct role in inhibiting the function of 
virulence factors and toxins. For example, 
antibodies can neutralize the toxicity of 
Hla or interfere with heme-iron scaveng-
ing mediated by IsdB and IsdA (Bubeck 
Wardenburg and Schneewind, 2008; Kim 
et al., 2010). Moreover, antibodies against 
several antigens have been shown to medi-
ate opsonophagocytosis (Stranger-Jones 
et al., 2006). From the clinical point of 
view, the scenario is much less clear. It is 
very well know that most individuals have 
circulating antibodies to S. aureus (Dryla 
et al., 2005; Clarke et al., 2006; Verkaik 
et al., 2009), however it is not known if they 
confer any protective immunity (Hermos 
et al., 2010). In our mind, an indication 
that antibodies do play, at least, a partial 
role in protecting humans against severe 
staphylococcal infections, comes from the 
observation that colonized patients present 
milder disease outcomes as compared to 
non-colonized patients (Wertheim et al., 
2004). Indeed, colonized subjects have 
been shown to have higher antibodies 
titers against several staphylococcal anti-
gens (Verkaik et al., 2009). Finally, sera from 
vaccines of StaphVax trials were found to 
mediate opsonophagocytosis and human 
sera of volunteers immunized with CP5 to 
confer passive protection in a murine infec-
tion model (Fattom et al., 1996, 2004). As 
already discussed for active vaccination 
strategies, failure of trials conducted with 
passive immunization may be due to the 
insufficient efficacy achieved targeting sin-
gle antigens. In addition, immune evasion 
mechanisms deployed by S. aureus, may 
abolish or dampen anti-S. aureus humoral 
responses in humans (Serruto et al., 2010a; 
Kim et al., 2012).
S. aureuS immune eVAsion 
fActors mAy represent A mAjor 
chAllenge in deVeloping 
efficAcious VAccines
S. aureus expresses a plethora of factors 
which, in different manners, inhibit the host 
immune response against the pathogen. 
Among them, the IgG-binding proteins SpA 
and Sbi, and complement-binding factors 
have been shown to efficiently interfere with 
antibody-mediated protection mechanisms 
(Serruto et al., 2010a; Kim et al., 2012). A 
critical aspect of some of these factors is 
2006). Importantly, in this model IsdB, the 
candidate tested by Merck in clinical trials, 
failed to generate protective immunity. The 
additive efficacy may be due to the different 
functions played by the four antigens in S. 
aureus virulence. This hypothesis is sup-
ported by the observation that a S. aureus 
SrtA knockout mutant, which lacks all the 
LPXTG-containing proteins (including 
IsdB, IsdA, SdrD, and SdrE), is less virulent 
than any mutant of individual LPXTG pro-
teins (Cheng et al., 2009). Stranger-Jones 
et al. (2006) also tested the protective effi-
cacy of several other S. aureus antigens in 
a murine renal abscess model in terms of 
bacterial load reduction. ClfA, the target of 
two clinical trials based on passive immu-
nization, was found to be inferior to IsdB. 
Therefore, it is conceivable to assume that 
strategies targeting ClfA only, may not be 
sufficiently protective. In a more recent 
paper two protein combinations (ClfA, 
FnBPB, and SdrD) and (ClfA, FnBPB, 
SdrD, and a non-toxigenic form of protein 
A, SpAKKAA) were shown to be highly pro-
tective in two different animal models of 
staphylococcal infection (Kim et al., 2011). 
Interestingly, the four-component com-
bination elicited greater protection than 
the trivalent vaccine. Similar results were 
observed with passive immunization stud-
ies, such as the antibody combination of 
ClfA and FnBPA (Arrecubieta et al., 2008). 
Our internal research with several antigens 
known in the literature as well as novel can-
didates confirms that, in general, combina-
tions generate greater protection than single 
antigens (unpublished data).
protectiVe mechAnisms AgAinst 
S. aureuS remAin to be 
elucidAted
The lack of correlates of protection for S. 
aureus is one of the major challenges for 
vaccine design and development. The fail-
ures of passive immunization strategies in 
clinical trials, advocate against an important 
role for antibodies in mediating protection 
against S. aureus. However, we believe that 
both preclinical and clinical data suggest 
that humoral responses play, at least, a par-
tial role in protecting against the pathogen. 
Passive transfer of antibodies raised against 
different staphylococcal antigens (e.g., 
Hla, IsdA, IsdB) in animal models, confers 
protection against the infection (Bubeck 
Wardenburg and Schneewind, 2008; Kim 
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animal infection models have been estab-
lished for assessing preclinical protective 
efficacy of vaccines, they may not optimally 
resemble natural infections in humans.
Accumulating literature is unraveling 
S. aureus pathogenic and immune evasion 
mechanisms. It will be important to use 
this information to target critical factors 
involved in these processes with next gen-
eration vaccines and to develop improved 
animal models and surrogates of protection. 
Although the nature of protective immu-
nity against the pathogen in humans is not 
known, animal studies as well as clinical 
observations indicate that both humoral 
as well as cell-mediated immunity are 
involved.
On the basis of that, we propose a 
model (Figure 1) in which vaccine effi-
cacy is gained through three major immune 
responses: (i) antibodies to directly inhibit 
bacterial viability and/or toxicity; (ii) anti-
bodies to mediate opsonophagocytosis; and 
(iii) cell-mediated immunity to stimulate 
recruitment of phagocytes at the site of 
the infection. It is very likely that only a 
combination of staphylococcal antigens 
Th1/Th17 adaptive immunity,  suggesting 
that cell-mediated focused vaccines 
could effectively protect against S. aureus 
infections.
AdjuVAnts mAy be importAnt to 
steer the right response AgAinst 
S. aureuS
Traditionally, adjuvants have been used 
to increase antibody-mediated responses. 
Aluminum hydroxyde (alum), oil-in-water 
emulsions (e.g., MF59 and AS03), have been 
shown to increase antibody titers, effective-
ness, and even functionality (Galli et al., 
2009; Jones, 2009; Dormitzer et al., 2011). 
However, the important role of adjuvants in 
stimulating T-cell responses is also becom-
ing clear. Recently, the response generated 
by MF59 was demonstrated to be skewed 
toward Th1 by the addition of E6020, a 
synthetic analog of MPL (monophosphoryl 
lipid A; Baudner et al., 2009; Dormitzer 
et al., 2011). In another study, IC31, a KLK 
peptide plus non-CpG oligonucleotide, 
was demonstrated to, conversely to alum, 
induce strong Th1 and Th17 responses 
(Kamath et al., 2008). Therefore, on top of 
the proper antigen combination, design of 
adjuvant formulations inducing higher and 
more functional antibodies, and stimulat-
ing T-cell-mediated immunity will certainly 
be another critical area of investigation.
conclusion
In our opinion, the spreading fear that an 
efficacious vaccine against S. aureus is not 
feasible, is not justified. Doubts expressed 
by several scientists are obviously due to 
the numerous failures in clinical trials and 
to the lack of known correlates of protec-
tion in humans (Patti, 2011; Proctor, 2012; 
Spellberg and Daum, 2011). Furthermore, 
concerns are also based on the observa-
tion that failed vaccines were assumed to 
be efficacious in animal models. However, 
vaccines tested in humans so far generated 
only partial protection against staphylococ-
cal infection in animal models. All vaccines 
tested in clinical trials targeted a single S. 
aureus component. Studies using antigen 
combinations have shown greater efficacy 
than single antigen vaccines in animal mod-
els. Therefore, multivalent vaccines will 
likely work better in humans as well. At the 
same time, we should be cautious in making 
direct correlations between animal studies 
and clinical trials. Indeed, although several 
with different properties and functions 
formulated with adjuvants able to elicit a 
potent antibody production, but also the 
proper cellular response, will satisfy the 
three criteria.
In conclusion, we are confident that 
by performing extensive preclinical work, 
using different animal models, readouts, 
and challenge strains, S. aureus vaccines 
with much greater chances of success in 
clinical trials can be developed.
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